Efficacy of delayed-release Mesalamine 4.8g/d (800mg tablet) for treatment of moderate UC in patients with a history of difficult to treat disease: Analysis of 3 double-blind, active-controlled trials
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.